logo

Press Releases

    • 27 DEC 2016

    PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

    LAGUNA HILLS, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that recent research performed at the Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg

    Read more →
    • 15 DEC 2016

    PharmaCyte Biotech Submits Pre-IND Meeting Package to FDA

    LAGUNA HILLS, Calif., Dec. 15, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted its pre-Investigational New Drug (pre-IND) meeting package to the U.S. Food and Drug Administration (FDA) for PharmaCyte’s

    Read more →
    • 07 DEC 2016

    PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principal Investigator

    LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the first article in a series of Q&A articles that will be conducted with some of the key team

    Read more →
    • 29 NOV 2016

    PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy

    LAGUNA HILLS, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S.

    Read more →
    • 16 NOV 2016

    PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial

    NEW YORK, NY — (Marketwired) — 11/16/16 — PharmaCyte Biotech (OTCQB: PMCB) has arrived at the door of U.S. FDA and awaits a pre-IND meeting with the agency. After years of surrounding its signature live-cell encapsulation technology, Cell-in-a-Box®, with some of the brightest minds in pancreatic cancer and fine-tuning its therapy and clinical trial design,

    Read more →
    • 14 NOV 2016

    University of Northern Colorado Presenting PharmaCyte Biotech’s Cannabis Research at the 2017 American Chemical Society National Meeting

    LAGUNA HILLS, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has submitted abstracts for the presentation of two scientific

    Read more →
    • 01 NOV 2016

    PharmaCyte Biotech Requests Pre-IND Meeting with FDA for its Pancreatic Cancer Clinical Trial

    LAGUNA HILLS, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has submitted a request for a pre-IND meeting with the U. S. Food and Drug Administration (FDA)

    Read more →
    • 24 OCT 2016

    PharmaCyte Biotech Selects Dr. Manuel Hidalgo as Principal Investigator for Its Pancreatic Cancer Clinical Trial

    LAGUNA HILLS, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Manuel Hidalgo, MD, PhD has agreed to serve as the Principal Investigator (PI) for PharmaCyte’s clinical trial in

    Read more →
    • 10 OCT 2016

    PharmaCyte Biotech Cannabinoid Research Shows Promise for Success

    LAGUNA HILLS, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has advanced into a new and promising phase of research at the University of Northern Colorado (UNCO)

    Read more →
    • 15 SEP 2016

    PharmaCyte’s CEO Discusses Development of its Pancreatic Cancer Therapy

    LAGUNA HILLS, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today addressed shareholders on the development of PharmaCyte’s therapy for advanced pancreatic cancer. The Chief Executive Officer of PharmaCyte, Kenneth L.

    Read more →